RUNX3 protein is overexpressed in human epithelial ovarian cancer

Nicole S. Nevadunsky, John S. Barbieri, Joseph Kwong, Melissa A. Merritt, William R. Welch, Ross S. Berkowitz, Samuel C. Mok

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: RUNX family genes, including RUNX3, are developmental regulators that are important in human cancers. The purpose of this study was to evaluate expression and oncogenic potential of RUNX3 in ovarian carcinoma. Methods: Immunohistochemical staining was performed on 60 malignant, 14 borderline, and 5 normal ovarian specimens. Correlation between RUNX3 expression with tumor histology was performed. RUNX3 expression was evaluated by quantitative real-time polymerase chain reaction (QRT-PCR) in microdissected normal and malignant epithelial ovarian tissues. Cell proliferation and viability studies were performed on cells expressing RUNX3 by lentiviral infection and cells with silenced RUNX3 expression by siRNA. Results: RUNX3 expression by immunohistochemistry was higher in serous ovarian carcinomas versus normal ovarian epithelium (P < 0.001). Immunofluorescent staining confirmed upregulation of cytoplasmic RUNX3 in ovarian cancer cell lines and tissues. QRT-PCR showed higher RUNX3 mRNA expression in microdissected borderline and malignant ovarian tumor tissues compared with the normal ovarian surface epithelial cells (HOSE) (P = 0.006 and P = 0.023). Forced RUNX3 expression by lentiviral gene delivery in ovarian cancer cells, SKOV3, that initially showed undetectable RUNX3 expression, resulted in increased cell viability (P = 0.043). Silencing RUNX3 expression by siRNA transfection into ovarian cancer cells, OVCAR429, initially expressing high levels of endogenous RUNX3 resulted in a decrease in proliferation (P = 0.021). Conclusion: These results suggest that RUNX3 has a role in cell proliferation and viability in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)325-330
Number of pages6
JournalGynecologic Oncology
Volume112
Issue number2
DOIs
StatePublished - Feb 2009
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Cell Survival
Small Interfering RNA
Real-Time Polymerase Chain Reaction
Proteins
Epithelium
Cell Proliferation
Staining and Labeling
Carcinoma
Neoplasms
Transfection
Histology
Up-Regulation
Epithelial Cells
Immunohistochemistry
Gene Expression
Cell Line
Messenger RNA
Ovarian epithelial cancer
Infection

Keywords

  • Oncogene
  • Ovarian cancer
  • RUNX3

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Nevadunsky, N. S., Barbieri, J. S., Kwong, J., Merritt, M. A., Welch, W. R., Berkowitz, R. S., & Mok, S. C. (2009). RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecologic Oncology, 112(2), 325-330. https://doi.org/10.1016/j.ygyno.2008.09.006

RUNX3 protein is overexpressed in human epithelial ovarian cancer. / Nevadunsky, Nicole S.; Barbieri, John S.; Kwong, Joseph; Merritt, Melissa A.; Welch, William R.; Berkowitz, Ross S.; Mok, Samuel C.

In: Gynecologic Oncology, Vol. 112, No. 2, 02.2009, p. 325-330.

Research output: Contribution to journalArticle

Nevadunsky, NS, Barbieri, JS, Kwong, J, Merritt, MA, Welch, WR, Berkowitz, RS & Mok, SC 2009, 'RUNX3 protein is overexpressed in human epithelial ovarian cancer', Gynecologic Oncology, vol. 112, no. 2, pp. 325-330. https://doi.org/10.1016/j.ygyno.2008.09.006
Nevadunsky NS, Barbieri JS, Kwong J, Merritt MA, Welch WR, Berkowitz RS et al. RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecologic Oncology. 2009 Feb;112(2):325-330. https://doi.org/10.1016/j.ygyno.2008.09.006
Nevadunsky, Nicole S. ; Barbieri, John S. ; Kwong, Joseph ; Merritt, Melissa A. ; Welch, William R. ; Berkowitz, Ross S. ; Mok, Samuel C. / RUNX3 protein is overexpressed in human epithelial ovarian cancer. In: Gynecologic Oncology. 2009 ; Vol. 112, No. 2. pp. 325-330.
@article{bf71918834f54cd1bc512c5a2f4e4b91,
title = "RUNX3 protein is overexpressed in human epithelial ovarian cancer",
abstract = "Objective: RUNX family genes, including RUNX3, are developmental regulators that are important in human cancers. The purpose of this study was to evaluate expression and oncogenic potential of RUNX3 in ovarian carcinoma. Methods: Immunohistochemical staining was performed on 60 malignant, 14 borderline, and 5 normal ovarian specimens. Correlation between RUNX3 expression with tumor histology was performed. RUNX3 expression was evaluated by quantitative real-time polymerase chain reaction (QRT-PCR) in microdissected normal and malignant epithelial ovarian tissues. Cell proliferation and viability studies were performed on cells expressing RUNX3 by lentiviral infection and cells with silenced RUNX3 expression by siRNA. Results: RUNX3 expression by immunohistochemistry was higher in serous ovarian carcinomas versus normal ovarian epithelium (P < 0.001). Immunofluorescent staining confirmed upregulation of cytoplasmic RUNX3 in ovarian cancer cell lines and tissues. QRT-PCR showed higher RUNX3 mRNA expression in microdissected borderline and malignant ovarian tumor tissues compared with the normal ovarian surface epithelial cells (HOSE) (P = 0.006 and P = 0.023). Forced RUNX3 expression by lentiviral gene delivery in ovarian cancer cells, SKOV3, that initially showed undetectable RUNX3 expression, resulted in increased cell viability (P = 0.043). Silencing RUNX3 expression by siRNA transfection into ovarian cancer cells, OVCAR429, initially expressing high levels of endogenous RUNX3 resulted in a decrease in proliferation (P = 0.021). Conclusion: These results suggest that RUNX3 has a role in cell proliferation and viability in ovarian cancer.",
keywords = "Oncogene, Ovarian cancer, RUNX3",
author = "Nevadunsky, {Nicole S.} and Barbieri, {John S.} and Joseph Kwong and Merritt, {Melissa A.} and Welch, {William R.} and Berkowitz, {Ross S.} and Mok, {Samuel C.}",
year = "2009",
month = "2",
doi = "10.1016/j.ygyno.2008.09.006",
language = "English (US)",
volume = "112",
pages = "325--330",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - RUNX3 protein is overexpressed in human epithelial ovarian cancer

AU - Nevadunsky, Nicole S.

AU - Barbieri, John S.

AU - Kwong, Joseph

AU - Merritt, Melissa A.

AU - Welch, William R.

AU - Berkowitz, Ross S.

AU - Mok, Samuel C.

PY - 2009/2

Y1 - 2009/2

N2 - Objective: RUNX family genes, including RUNX3, are developmental regulators that are important in human cancers. The purpose of this study was to evaluate expression and oncogenic potential of RUNX3 in ovarian carcinoma. Methods: Immunohistochemical staining was performed on 60 malignant, 14 borderline, and 5 normal ovarian specimens. Correlation between RUNX3 expression with tumor histology was performed. RUNX3 expression was evaluated by quantitative real-time polymerase chain reaction (QRT-PCR) in microdissected normal and malignant epithelial ovarian tissues. Cell proliferation and viability studies were performed on cells expressing RUNX3 by lentiviral infection and cells with silenced RUNX3 expression by siRNA. Results: RUNX3 expression by immunohistochemistry was higher in serous ovarian carcinomas versus normal ovarian epithelium (P < 0.001). Immunofluorescent staining confirmed upregulation of cytoplasmic RUNX3 in ovarian cancer cell lines and tissues. QRT-PCR showed higher RUNX3 mRNA expression in microdissected borderline and malignant ovarian tumor tissues compared with the normal ovarian surface epithelial cells (HOSE) (P = 0.006 and P = 0.023). Forced RUNX3 expression by lentiviral gene delivery in ovarian cancer cells, SKOV3, that initially showed undetectable RUNX3 expression, resulted in increased cell viability (P = 0.043). Silencing RUNX3 expression by siRNA transfection into ovarian cancer cells, OVCAR429, initially expressing high levels of endogenous RUNX3 resulted in a decrease in proliferation (P = 0.021). Conclusion: These results suggest that RUNX3 has a role in cell proliferation and viability in ovarian cancer.

AB - Objective: RUNX family genes, including RUNX3, are developmental regulators that are important in human cancers. The purpose of this study was to evaluate expression and oncogenic potential of RUNX3 in ovarian carcinoma. Methods: Immunohistochemical staining was performed on 60 malignant, 14 borderline, and 5 normal ovarian specimens. Correlation between RUNX3 expression with tumor histology was performed. RUNX3 expression was evaluated by quantitative real-time polymerase chain reaction (QRT-PCR) in microdissected normal and malignant epithelial ovarian tissues. Cell proliferation and viability studies were performed on cells expressing RUNX3 by lentiviral infection and cells with silenced RUNX3 expression by siRNA. Results: RUNX3 expression by immunohistochemistry was higher in serous ovarian carcinomas versus normal ovarian epithelium (P < 0.001). Immunofluorescent staining confirmed upregulation of cytoplasmic RUNX3 in ovarian cancer cell lines and tissues. QRT-PCR showed higher RUNX3 mRNA expression in microdissected borderline and malignant ovarian tumor tissues compared with the normal ovarian surface epithelial cells (HOSE) (P = 0.006 and P = 0.023). Forced RUNX3 expression by lentiviral gene delivery in ovarian cancer cells, SKOV3, that initially showed undetectable RUNX3 expression, resulted in increased cell viability (P = 0.043). Silencing RUNX3 expression by siRNA transfection into ovarian cancer cells, OVCAR429, initially expressing high levels of endogenous RUNX3 resulted in a decrease in proliferation (P = 0.021). Conclusion: These results suggest that RUNX3 has a role in cell proliferation and viability in ovarian cancer.

KW - Oncogene

KW - Ovarian cancer

KW - RUNX3

UR - http://www.scopus.com/inward/record.url?scp=58249097238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249097238&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.09.006

DO - 10.1016/j.ygyno.2008.09.006

M3 - Article

C2 - 18937968

AN - SCOPUS:58249097238

VL - 112

SP - 325

EP - 330

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -